title: Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report.
abstract: The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m(2) ) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t½.
authors.affiliation: Division of Pediatric Hematology/Oncology, University at Buffalo, Buffalo, NY, USA.
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Barth
authors.forename: Stanton
authors.initials: S
authors.lastname: Goldman
authors.forename: Lynette
authors.initials: L
authors.lastname: Smith
authors.forename: Sherrie
authors.initials: S
authors.lastname: Perkins
authors.forename: Bruce
authors.initials: B
authors.lastname: Shiramizu
authors.forename: Thomas G
authors.initials: TG
authors.lastname: Gross
authors.forename: Lauren
authors.initials: L
authors.lastname: Harrison
authors.forename: Warren
authors.initials: W
authors.lastname: Sanger
authors.forename: Mark B
authors.initials: MB
authors.lastname: Geyer
authors.forename: Lisa
authors.initials: L
authors.lastname: Giulino-Roth
authors.forename: Mitchell S
authors.initials: MS
authors.lastname: Cairo
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000097:blood*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006207:Half-Life; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D016393:Lymphoma, B-Cell / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D008727:Methotrexate / Q000627:therapeutic use; D009367:Neoplasm Staging; D010865:Pilot Projects; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D007770:L-Lactate Dehydrogenase; D011241:Prednisone; D008727:Methotrexate
keywords: CD20; non-Hodgkin lymphoma; pediatric; pharmacokinetics; rituximab